[{"id":"b0107240-c9ff-4b67-b853-211b0d9cdc8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469774","created_at":"2026-03-28T01:44:13.768Z","updated_at":"2026-03-28T01:44:13.768Z","phase":"Phase 1/2","brief_title":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07469774","lead_sponsor":"Biocity Biopharmaceutics Co., Ltd.","biomarkers":" EGFR • BRAF • ALK • MET • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • ALK • MET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/17/2026","start_date":" 03/17/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2026-03-13"},{"id":"3aba5b38-3db1-4e50-b966-dbbd60ad2e6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06863818","created_at":"2025-09-07T01:52:13.355Z","updated_at":"2025-09-07T01:52:13.355Z","phase":"","brief_title":"Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs","source_id_and_acronym":"NCT06863818","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" EGFR • HER-2 • MET • ERBB3 • NRG1 • ERBB4","pipe":"","alterations":" ","tags":["EGFR • HER-2 • MET • ERBB3 • NRG1 • ERBB4"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/10/2022","start_date":" 10/10/2022","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-03-07"},{"id":"ca7e4b34-6f76-4ea3-8c6b-e39973324752","acronym":"NRG-LU003","url":"https://clinicaltrials.gov/study/NCT03737994","created_at":"2023-11-21T21:15:46.432Z","updated_at":"2025-02-25T12:37:11.248Z","phase":"Phase 2","brief_title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03737994 - NRG-LU003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" ALK positive • MET amplification • ALK rearrangement","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • MET amplification • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 07/21/2021","primary_completion_date":" 07/21/2021","study_txt":" Completion: 12/02/2025","study_completion_date":" 12/02/2025","last_update_posted":"2025-02-24"},{"id":"9272430e-eab6-4fc0-8844-69d711337ecc","acronym":"ENDURE","url":"https://clinicaltrials.gov/study/NCT04892953","created_at":"2021-05-19T15:52:50.047Z","updated_at":"2025-02-25T13:40:30.743Z","phase":"Phase 2","brief_title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","source_id_and_acronym":"NCT04892953 - ENDURE","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK • MET • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["EGFR • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-21"},{"id":"1a5d5c5e-2d0c-4820-8c6b-6f33f98d1419","acronym":"INSIGHT 2","url":"https://clinicaltrials.gov/study/NCT03940703","created_at":"2021-01-18T19:24:17.010Z","updated_at":"2025-02-25T13:52:54.712Z","phase":"Phase 2","brief_title":"A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)","source_id_and_acronym":"NCT03940703 - INSIGHT 2","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • MET amplification","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Tepmetko (tepotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 09/19/2019","start_date":" 09/19/2019","primary_txt":" Primary completion: 05/11/2023","primary_completion_date":" 05/11/2023","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-20"},{"id":"cb7ed592-cf61-416e-86bf-22b417e0e5af","acronym":"M21-404","url":"https://clinicaltrials.gov/study/NCT05029882","created_at":"2021-09-01T14:52:59.151Z","updated_at":"2025-02-25T13:53:58.746Z","phase":"Phase 1","brief_title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab","source_id_and_acronym":"NCT05029882 - M21-404","lead_sponsor":"AbbVie","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • EGFR wild-type","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • telisotuzumab adizutecan (ABBV-400)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 520","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-20"},{"id":"6fa58343-5f41-4e65-b9b7-ed2e1d17361f","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06116682","created_at":"2023-11-03T20:12:32.614Z","updated_at":"2025-02-25T14:10:16.796Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06116682 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/19/2024","start_date":" 11/19/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-19"},{"id":"b727510f-e4dd-45d1-a75b-a7fd6215444a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03598244","created_at":"2021-01-18T17:41:26.385Z","updated_at":"2025-02-25T14:15:11.442Z","phase":"Phase 1","brief_title":"Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors","source_id_and_acronym":"NCT03598244","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/27/2018","start_date":" 11/27/2018","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-18"},{"id":"c3e9ec33-9883-4e28-b473-f95df1486329","acronym":"Lung-Map Screening Study","url":"https://clinicaltrials.gov/study/NCT03851445","created_at":"2021-01-18T19:00:27.801Z","updated_at":"2025-02-25T14:07:20.756Z","phase":"Phase 2/3","brief_title":"Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03851445 - Lung-Map Screening Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • MET • ROS1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion","tags":["EGFR • BRAF • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 10000","initiation":"Initiation: 02/06/2019","start_date":" 02/06/2019","primary_txt":" Primary completion: 01/28/2029","primary_completion_date":" 01/28/2029","study_txt":" Completion: 01/28/2029","study_completion_date":" 01/28/2029","last_update_posted":"2025-02-17"},{"id":"fc32aaa3-7f5b-404e-9923-86b9a8cde5d8","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06031688","created_at":"2023-09-11T16:10:36.199Z","updated_at":"2025-02-25T14:10:03.191Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06031688 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/08/2024","start_date":" 08/08/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2025-02-17"},{"id":"9e22f735-9f0d-4c3a-92fb-91f43ae1a4bd","acronym":"TROPION-LUNG01","url":"https://clinicaltrials.gov/study/NCT04656652","created_at":"2021-01-19T20:41:43.327Z","updated_at":"2025-02-25T14:59:32.426Z","phase":"Phase 3","brief_title":"Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)","source_id_and_acronym":"NCT04656652 - TROPION-LUNG01","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • PD-L1 • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET exon 14 mutation","tags":["EGFR • PD-L1 • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 590","initiation":"Initiation: 12/21/2020","start_date":" 12/21/2020","primary_txt":" Primary completion: 05/10/2024","primary_completion_date":" 05/10/2024","study_txt":" Completion: 06/21/2025","study_completion_date":" 06/21/2025","last_update_posted":"2025-02-13"},{"id":"7204e2a6-dc66-4d87-87cb-75b6b508cd0a","acronym":"KisMET-01","url":"https://clinicaltrials.gov/study/NCT05652868","created_at":"2022-12-15T14:58:22.414Z","updated_at":"2025-02-25T15:20:09.822Z","phase":"Phase 1","brief_title":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05652868 - KisMET-01","lead_sponsor":"Mythic Therapeutics","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYTX-011"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 03/23/2023","start_date":" 03/23/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-12"},{"id":"5f3b5bbb-9aff-4571-a252-57e8a1171808","acronym":"CHRYSALIS-2","url":"https://clinicaltrials.gov/study/NCT04077463","created_at":"2021-01-18T19:58:05.927Z","updated_at":"2025-02-25T15:34:28.760Z","phase":"Phase 1","brief_title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04077463 - CHRYSALIS-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 701","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 02/03/2025","primary_completion_date":" 02/03/2025","study_txt":" Completion: 06/03/2026","study_completion_date":" 06/03/2026","last_update_posted":"2025-02-11"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"aef3f3cb-aa50-40d2-b1b1-727aae5c68fd","acronym":"CHRYSALIS","url":"https://clinicaltrials.gov/study/NCT02609776","created_at":"2021-01-17T17:17:24.122Z","updated_at":"2025-02-25T15:33:33.328Z","phase":"Phase 1","brief_title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02609776 - CHRYSALIS","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" ALK • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive","tags":["ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 751","initiation":"Initiation: 05/24/2016","start_date":" 05/24/2016","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-11"},{"id":"242a6457-aef1-4b8b-890a-953bd32e515a","acronym":"SAVANNAH","url":"https://clinicaltrials.gov/study/NCT03778229","created_at":"2021-01-18T18:41:19.683Z","updated_at":"2025-02-25T15:34:16.664Z","phase":"Phase 2","brief_title":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","source_id_and_acronym":"NCT03778229 - SAVANNAH","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 367","initiation":"Initiation: 01/09/2019","start_date":" 01/09/2019","primary_txt":" Primary completion: 08/23/2024","primary_completion_date":" 08/23/2024","study_txt":" Completion: 05/28/2025","study_completion_date":" 05/28/2025","last_update_posted":"2025-02-10"},{"id":"4811680a-497e-488d-8abd-34a9b22c5b1c","acronym":"TeliMET NSCLC-01","url":"https://clinicaltrials.gov/study/NCT04928846","created_at":"2021-06-16T18:52:53.966Z","updated_at":"2025-02-25T15:35:07.629Z","phase":"Phase 3","brief_title":"A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04928846 - TeliMET NSCLC-01","lead_sponsor":"AbbVie","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • MET overexpression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Emrelis (telisotuzumab vedotin-tllv)"],"overall_status":"Recruiting","enrollment":" Enrollment 698","initiation":"Initiation: 03/25/2022","start_date":" 03/25/2022","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2025-02-10"},{"id":"74af1789-bdc4-49be-8227-be00ab7f39a0","acronym":"PALOMA","url":"https://clinicaltrials.gov/study/NCT04606381","created_at":"2021-01-19T20:31:31.743Z","updated_at":"2025-02-25T15:34:47.299Z","phase":"Phase 1","brief_title":"A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies","source_id_and_acronym":"NCT04606381 - PALOMA","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" MET","pipe":" | ","alterations":" EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 11/10/2020","start_date":" 11/10/2020","primary_txt":" Primary completion: 07/11/2024","primary_completion_date":" 07/11/2024","study_txt":" Completion: 10/21/2025","study_completion_date":" 10/21/2025","last_update_posted":"2025-02-10"},{"id":"1bd3b65f-3d27-4d52-a00c-7ebcb1b64c6b","acronym":"KUNPENG","url":"https://clinicaltrials.gov/study/NCT04258033","created_at":"2021-01-18T20:41:41.946Z","updated_at":"2025-02-25T16:37:45.457Z","phase":"Phase 2","brief_title":"A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)","source_id_and_acronym":"NCT04258033 - KUNPENG","lead_sponsor":"Beijing Pearl Biotechnology Limited Liability Company","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 01/17/2020","start_date":" 01/17/2020","primary_txt":" Primary completion: 05/14/2024","primary_completion_date":" 05/14/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"dab562b9-279d-4fe8-b2fc-7ee0c721ed02","acronym":"KUNPENG-2","url":"https://clinicaltrials.gov/study/NCT05989542","created_at":"2023-08-14T14:10:14.391Z","updated_at":"2025-02-25T16:40:06.600Z","phase":"Phase 3","brief_title":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)","source_id_and_acronym":"NCT05989542 - KUNPENG-2","lead_sponsor":"Beijing Pearl Biotechnology Limited Liability Company","biomarkers":" EGFR • KRAS • ALK • MET • ROS1","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ROS1 rearrangement","tags":["EGFR • KRAS • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 06/29/2023","start_date":" 06/29/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-06"},{"id":"ece1e947-6ee1-43ee-ad69-399f7ff3106a","acronym":"CoC","url":"https://clinicaltrials.gov/study/NCT04606771","created_at":"2021-01-19T20:31:36.655Z","updated_at":"2025-02-25T17:00:42.361Z","phase":"Phase 2","brief_title":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","source_id_and_acronym":"NCT04606771 - CoC","lead_sponsor":"AstraZeneca","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/28/2020","start_date":" 09/28/2020","primary_txt":" Primary completion: 12/21/2022","primary_completion_date":" 12/21/2022","study_txt":" Completion: 03/28/2025","study_completion_date":" 03/28/2025","last_update_posted":"2025-02-03"},{"id":"24c0fcb4-b357-4530-a6a0-668b57518e71","acronym":"ARC-27","url":"https://clinicaltrials.gov/study/NCT06120075","created_at":"2023-11-07T16:14:23.781Z","updated_at":"2025-02-25T17:32:32.864Z","phase":"Phase 1","brief_title":"A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies","source_id_and_acronym":"NCT06120075 - ARC-27","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" EGFR • PD-L1 • ALK • MET • RET • ROS1 • STK11 • NTRK","pipe":" | ","alterations":" EGFR mutation • STK11 mutation • ALK mutation","tags":["EGFR • PD-L1 • ALK • MET • RET • ROS1 • STK11 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • STK11 mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Yutuo (zimberelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 01/19/2024","start_date":" 01/19/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-01-30"},{"id":"af8a3284-49b9-490f-b1b7-982ed6e7b88b","acronym":"POTENT","url":"https://clinicaltrials.gov/study/NCT05782361","created_at":"2023-03-23T14:03:00.081Z","updated_at":"2025-02-25T16:18:40.803Z","phase":"Phase 1","brief_title":"POTENT - Tepotinib in Combination with Pembrolizumab in NSCLC","source_id_and_acronym":"NCT05782361 - POTENT","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-10-01"},{"id":"0b5f1810-21e0-4d81-99c2-2da131cdd433","acronym":"VISION","url":"https://clinicaltrials.gov/study/NCT02864992","created_at":"2021-01-17T17:11:42.537Z","updated_at":"2025-02-25T16:05:05.696Z","phase":"Phase 2","brief_title":"Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)","source_id_and_acronym":"NCT02864992 - VISION","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tepmetko (tepotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 337","initiation":"Initiation: 09/13/2016","start_date":" 09/13/2016","primary_txt":" Primary completion: 05/16/2022","primary_completion_date":" 05/16/2022","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2024-08-30"}]